Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OA-235i in NASH
NCT05680233Phase 1Completed
- Sponsor
- Oasis Pharmaceuticals, LLC
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OA-235i in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Oasis Pharmaceuticals, LLC. Primary endpoint: Frequency and severity of Adverse Events and Serious Adverse Events at 30 Days. Started Mar 2023; status: completed.
02
Drugs
OA-235i
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05680233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680233.